M.D. Anderson Cancer Center
To find out if receiving standard chemotherapy (doxorubicin and trabectedin) can extend the cancer-free survival of patients with Stage 1b/2 uterine leiomyosarcoma who had surgery that fully removed the tumor.
Primary Objective: To evaluate disease-free survival (DFS) in patients with AJCC stage 1b, 2 and 3 uterine leiomyosarcoma receivingadjuvant chemotherapy by standard-of-care doxorubicin and trabectedin for 6 cycles Secondary Objectives: * To assess overall survival (OS) in patients with AJCC stage 1b, 2 and 3 uterine leiomyosarcoma receiving adjuvant chemotherapy by standard-of-care doxorubicin and trabectedin for 6 cycles * To characterize treatment-related toxicity according to Common Terminology Criteria for Adverse Events (CTCAE), in patients with AJCC stage 1b, 2 and 3 uterine leiomyosa…
Inclusion Criteria: * Patients must have histologically confirmed uterine leiomyosarcoma * Patients must have localized tumors, AJCC stages 1b to 3 according to the AJCC uterine sarcoma staging system (high risk of relapse population) * Patients must have had complete surgical resection of tumor within 3 months prior to initiation of adjuvant chemotherapy, complete surgical resection includes at least a total hysterectomy * Patients must have no evidence of residual disease, as proven by CT Chest-Abdomen-Pelvic within 30 days. * Patients must have no history of pelvic radiation (hematologic t…
Given by IV Infusion
Given by IV Infusion
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.